Long-term virologic suppression despite presence of resistance-associated mutations among perinatally HIV-infected youth

Tiffeny T. Smith, Alice J. Hsu, Nancy Hutton, Faith Womble, Allison Lorna Agwu

Research output: Contribution to journalArticle

Abstract

Background: There is limited information on long-term consequences of continuing combination antiretroviral therapy (cART) consisting of 3 and 2920 copies/mL, respectively. All patients harbored reverse transcriptase, and 57% harbored protease mutations. The median duration of VS was 37 months (interquartile range: 22-66). Fifteen patients (41%) had VB. The median change in CD4 count during VS was +82 cells/mm3 at 12 months. The risk of VB was lower in those who gained ≥50 cells/mm3 by 12 months (unadjusted hazards ratio: 0.271; 95% confidence interval: 0.0825-0.893; P, 0.032); however, this was not significant in the adjusted model. Conclusions: VS was maintained for a median of 3 years without decline in CD4 count. Independent risk factors for VB were not identified; however, there was a trend toward higher risk of VB in those without CD4 gain of ≥50 cells/mm3 by 12 months. Suppressive cART containing

Original languageEnglish (US)
Pages (from-to)1365-1368
Number of pages4
JournalPediatric Infectious Disease Journal
Volume34
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

HIV
CD4 Lymphocyte Count
Mutation
RNA-Directed DNA Polymerase
Peptide Hydrolases
Confidence Intervals
Therapeutics

Keywords

  • antiretroviral
  • HIV
  • perinatal infection

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases
  • Microbiology (medical)

Cite this

Long-term virologic suppression despite presence of resistance-associated mutations among perinatally HIV-infected youth. / Smith, Tiffeny T.; Hsu, Alice J.; Hutton, Nancy; Womble, Faith; Agwu, Allison Lorna.

In: Pediatric Infectious Disease Journal, Vol. 34, No. 12, 01.12.2015, p. 1365-1368.

Research output: Contribution to journalArticle

@article{8f52154bba7a4d34af779a0efc62cfea,
title = "Long-term virologic suppression despite presence of resistance-associated mutations among perinatally HIV-infected youth",
abstract = "Background: There is limited information on long-term consequences of continuing combination antiretroviral therapy (cART) consisting of 3 and 2920 copies/mL, respectively. All patients harbored reverse transcriptase, and 57{\%} harbored protease mutations. The median duration of VS was 37 months (interquartile range: 22-66). Fifteen patients (41{\%}) had VB. The median change in CD4 count during VS was +82 cells/mm3 at 12 months. The risk of VB was lower in those who gained ≥50 cells/mm3 by 12 months (unadjusted hazards ratio: 0.271; 95{\%} confidence interval: 0.0825-0.893; P, 0.032); however, this was not significant in the adjusted model. Conclusions: VS was maintained for a median of 3 years without decline in CD4 count. Independent risk factors for VB were not identified; however, there was a trend toward higher risk of VB in those without CD4 gain of ≥50 cells/mm3 by 12 months. Suppressive cART containing",
keywords = "antiretroviral, HIV, perinatal infection",
author = "Smith, {Tiffeny T.} and Hsu, {Alice J.} and Nancy Hutton and Faith Womble and Agwu, {Allison Lorna}",
year = "2015",
month = "12",
day = "1",
doi = "10.1097/INF.0000000000000895",
language = "English (US)",
volume = "34",
pages = "1365--1368",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Long-term virologic suppression despite presence of resistance-associated mutations among perinatally HIV-infected youth

AU - Smith, Tiffeny T.

AU - Hsu, Alice J.

AU - Hutton, Nancy

AU - Womble, Faith

AU - Agwu, Allison Lorna

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background: There is limited information on long-term consequences of continuing combination antiretroviral therapy (cART) consisting of 3 and 2920 copies/mL, respectively. All patients harbored reverse transcriptase, and 57% harbored protease mutations. The median duration of VS was 37 months (interquartile range: 22-66). Fifteen patients (41%) had VB. The median change in CD4 count during VS was +82 cells/mm3 at 12 months. The risk of VB was lower in those who gained ≥50 cells/mm3 by 12 months (unadjusted hazards ratio: 0.271; 95% confidence interval: 0.0825-0.893; P, 0.032); however, this was not significant in the adjusted model. Conclusions: VS was maintained for a median of 3 years without decline in CD4 count. Independent risk factors for VB were not identified; however, there was a trend toward higher risk of VB in those without CD4 gain of ≥50 cells/mm3 by 12 months. Suppressive cART containing

AB - Background: There is limited information on long-term consequences of continuing combination antiretroviral therapy (cART) consisting of 3 and 2920 copies/mL, respectively. All patients harbored reverse transcriptase, and 57% harbored protease mutations. The median duration of VS was 37 months (interquartile range: 22-66). Fifteen patients (41%) had VB. The median change in CD4 count during VS was +82 cells/mm3 at 12 months. The risk of VB was lower in those who gained ≥50 cells/mm3 by 12 months (unadjusted hazards ratio: 0.271; 95% confidence interval: 0.0825-0.893; P, 0.032); however, this was not significant in the adjusted model. Conclusions: VS was maintained for a median of 3 years without decline in CD4 count. Independent risk factors for VB were not identified; however, there was a trend toward higher risk of VB in those without CD4 gain of ≥50 cells/mm3 by 12 months. Suppressive cART containing

KW - antiretroviral

KW - HIV

KW - perinatal infection

UR - http://www.scopus.com/inward/record.url?scp=84966546679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966546679&partnerID=8YFLogxK

U2 - 10.1097/INF.0000000000000895

DO - 10.1097/INF.0000000000000895

M3 - Article

VL - 34

SP - 1365

EP - 1368

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 12

ER -